Cargando…

Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings

INTRODUCTION: The management of neuromuscular blockade (NMB) has evolved over time and remains a critical component of general anesthesia. However, NMB use varies by patient and procedural characteristics, clinical practices, protocols, and drug access. National utilization patterns are unknown. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bash, Lori D., Turzhitsky, Vladimir, Black, Wynona, Urman, Richard D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317140/ https://www.ncbi.nlm.nih.gov/pubmed/34319550 http://dx.doi.org/10.1007/s12325-021-01835-2

Ejemplares similares

A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US
por: Jiang, Yiling, et al.
Publicado: (2021)

Novel drug development for neuromuscular blockade
por: Prabhakar, Amit, et al.
Publicado: (2016)

Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study
por: Domenech, Gonzalo, et al.
Publicado: (2019)

Neuromuscular Blockade Agents Reversal with Sugammadex Compared to Neostigmine in the Living Kidney Donors
por: Quang, Thuy Luu, et al.
Publicado: (2019)

REVersal of nEuromusculAr bLocking Agents in Patients Undergoing General Anaesthesia (REVEAL Study)
por: Greco, Massimiliano, et al.
Publicado: (2023)

Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents
por: Higashi, Michiko, et al.
Publicado: (2019)

Observational study on patterns of neuromuscular blockade reversal
por: Dubovoy, Timur, et al.
Publicado: (2016)

Clinical Impact of Sugammadex in the Reversal of Neuromuscular Blockade
por: Goodner, Joshua A, et al.
Publicado: (2021)

Sugammadex, a Neuromuscular Blockade Reversal Agent, Causes Neuronal Apoptosis in Primary Cultures
por: Palanca, José M., et al.
Publicado: (2013)

Does deep neuromuscular blockade during laparoscopy procedures change patient, surgical, and healthcare resource outcomes? A systematic review and meta-analysis of randomized controlled trials
por: Raval, Amit D., et al.
Publicado: (2020)

Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome
por: Ledowski, Thomas, et al.
Publicado: (2013)

Cardiac arrest after administration of sugammadex as neuromuscular blockade reversal agent and full recovery from anesthesia
por: Samara, Evangelia, et al.
Publicado: (2020)

Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives
por: Carron, Michele, et al.
Publicado: (2017)

Asystole Following Neuromuscular Blockade Reversal in Cardiac Transplant Patients
por: Nkemngu, Njinkeng J
Publicado: (2017)

Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade
por: Luo, Jie, et al.
Publicado: (2018)

Sugammadex to Reverse Neuromuscular Blockade in a Child with a Past History of Cardiac Transplantation
por: Miller, Karen, et al.
Publicado: (2017)

The Use of Muscle Relaxants and Reversal Agents in a Setting Without Cost Restrictions: Experience from a Tertiary Academic Hospital in the Netherlands
por: Martini, Chris H, et al.
Publicado: (2022)

Sugammadex to reverse neuromuscular blockade and provide optimal conditions for motor-evoked potential monitoring
por: Trifa, Mehdi, et al.
Publicado: (2017)

Reversal agent is mandatory even with neuromuscular monitoring!
por: Mehandale, Sripada Gopalakrishna, et al.
Publicado: (2018)

Successful Neuromuscular Blockade Reversal Using Sugammadex and Neostigmine Failed to Prevent Myasthenic Crisis After Emergency Surgery: A Case Report
por: Haddad, Daniel, et al.
Publicado: (2022)

Neuromuscular blockade in the elderly patient
por: Lee, Luis A, et al.
Publicado: (2016)

Intraoperative Monitoring of Neuromuscular Blockade
por: Motamed, Cyrus
Publicado: (2023)

Comparison of recovery profiles in patients with Parkinson's disease for 2 types of neuromuscular blockade reversal agent following deep brain stimulator implantation
por: Park, Yong-Seok, et al.
Publicado: (2019)

Negative Pressure Pulmonary Edema after Reversing Rocuronium-Induced Neuromuscular Blockade by Sugammadex
por: Suzuki, Manzo, et al.
Publicado: (2014)

Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients
por: Woo, Tiffany, et al.
Publicado: (2013)

Economic analysis of sugammadex versus neostigmine for reversal of neuromuscular blockade for laparoscopic surgery in China
por: Ren, Maodong, et al.
Publicado: (2020)

Is neostigmine safe and effective for neuromuscular blockade reversal in patients recovering from general anesthesia?
por: Wu, Jiangfeng, et al.
Publicado: (2022)

Improved oxygenation after discontinuing neuromuscular blockade
por: Willson, D. F., et al.
Publicado: (1997)

Flexible organic frameworks sequester neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo
por: Wu, Yan, et al.
Publicado: (2022)

Residual neuromuscular blockade and late neuromuscular blockade at the post-anesthetic recovery unit: prospective cohort study
por: Gonçalves, Pedro Marcos Silva e, et al.
Publicado: (2020)

The Effect of Neuromuscular Blockade Reversal Agents on Postoperative Pulmonary Complications in Patients undergoing Femur Fracture Repair Surgery: A Retrospective Observational Study
por: Cho, Sung-Ae, et al.
Publicado: (2023)

New Drug Developments for Neuromuscular Blockade and Reversal: Gantacurium, CW002, CW011, and Calabadion
por: de Boer, Hans Donald, et al.
Publicado: (2018)

Should we Routinely Reverse Neuromuscular Blockade with Sugammadex in Patients with a History of Heart Transplantation?
por: Yuki, Koichi, et al.
Publicado: (2020)

Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain
por: Martinez-Ubieto, J., et al.
Publicado: (2021)

Reply to “Is neostigmine safe and effective for neuromuscular blockade reversal in patients recovering from general anesthesia?”
por: Ji, Wentao, et al.
Publicado: (2022)

Reversing Neuromuscular Blockade without Nerve Stimulator Guidance in a Postsurgical ICU—An Observational Study
por: Calef, Andrea, et al.
Publicado: (2023)

An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant
por: Paredes, Stephania, et al.
Publicado: (2023)

Factors Associated With Inter-Hospital Variability of Inpatient Antibiotic Use in a Cohort of US Hospitals
por: Baggs, James, et al.
Publicado: (2015)

Sugammadex as a reversal agent for neuromuscular block: an evidence-based review
por: Schaller, Stefan Josef, et al.
Publicado: (2013)

Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications
por: Cho, Sung-Ae, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ot06fvd1v2shjkag9r9i743as6